Researchers have identified a new potential immunotherapy target in pancreatic cancer, which has been notoriously resistant to treatment with immune checkpoint blockade drugs effective against a variety of other cancers.
All news from Immuno Haematology & Blood Transfusion
Scientists have created the first retroviral CRISPR-Cas9 gene editing library to explore the regulation of mouse T cells, which are key cells in the immune system. Researchers from the Wellcome Sanger Institute and their collaborators have mapped the most important genes for controlling T helper cells and identified several new regulatory genes.
The University of North Carolina Lineberger Comprehensive Cancer Center researchers have identified a potential way to target a subtype of acute myeloid leukemia (AML) using chimeric antigen receptor (CAR) T-cell therapy, a form of immunotherapy in which patients' immune cells are genetically engineered to recognize and track their cancer.
A new mechanism for activating the immune system against cancer cells allows the cells to detect and destroy cancer cells better than before, according to a study published this week in the journal Nature .
Researchers have found a stem cell enzyme copy edits more than 20 tumor types, providing a new therapeutic target for preventing cancer cell resistance to chemotherapy and radiation.
After infections tied to unapproved stem cell treatments sent 12 people to the hospital this past year, the U.S. Food and Drug Administration on Thursday issued a stern warning about the products.
AIST medical scientists have presented novel pathways involving T immune cell exhaustion, providing evidence and rationale for designing optimal strategies for immune checkpoint blockades in cancer patients. They succeeded in distinguishing the hepatocellular carcinoma group from the exhausted tumor-infiltrating immune cell composition of liver cancer patients.
People with a certain type of lymphoma will not be able to receive a targeted cancer drug on the NHS in England. The National Institute for Health and Care Excellence (NICE) concluded that giving brentuximab vedotin (Adcetris) to people with a type of lymphoma after they've had another treatment is not cost effective.
Natural killer (NK) cells are attractive candidates for allogeneic cell-based immunotherapy due to their potent antitumor effector function and good safety profile. NK cells express killer immunoglobulin-like receptors (KIRs) and the NKG2A receptor important for NK cells education as well as providing inhibitory signals upon encountering HLA-expressing target cells. Multiple myelomas (MM) is an example of a tumor expressing relatively high levels of HLA molecules.
Acute graft- vs. host disease (GVHD) is an important cause of morbidity and death after allogeneic hematopoietic cell transplantation (HCT). We identify a new approach to prevent GVHD that impairs monocyte-derived dendritic cell (moDC) alloactivation of T cells, yet preserves graft- vs.-leukemia (GVL). Exceeding endoplasmic reticulum (ER) capacity results in a spliced form of X-box binding protein-1 (XBP-1s).
St. Jude Children's Research Hospital scientists have discovered a subset of helper T cells that may help to redefine understanding and treatment of chronic, debilitating inflammatory disorders. The research appears today as an advance online publication in the journal Nature.
The U.S. Food and Drug Administration today approved Elzonris (tagraxofusp-erzs) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients, two years of age and older.